Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease

19Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.
Get full text

Abstract

A HIV infected patient was treated for stage IVB Hodgkin's lymphoma by ABVD (doxorubicine, bleomycine, vinblastine, dacarbazine) chemotherapy and lopinavir-ritonavir based antiretroviral therapy inducing profound life-threatening neutropenia. Vinblastine and lopinavir-ritonavir interaction was managed with lopinavir-ritonavir interruption around chemotherapy administration, with complete remission and immunovirological success after six cycles. This unrecorded strategy is discussed. © 2007 The Authors.

Cite

CITATION STYLE

APA

Makinson, A., Martelli, N., Peyrière, H., Turriere, C., Moing, V. L., & Reynes, J. (2007). Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin’s disease. European Journal of Haematology, 78(4), 358–360. https://doi.org/10.1111/j.1600-0609.2007.00827.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free